University of Tasmania Study: ARBs Linked to 28% Lower Dementia Risk Than ACE Inhibitors

A groundbreaking analysis led by researchers at the University of Tasmania has uncovered compelling evidence that certain blood pressure medications could play a pivotal role in lowering dementia risk. Drawing from one of Australia's largest longitudinal health studies, the 45 and Up Study, this research highlights how angiotensin receptor blockers (ARBs), a class of antihypertensive drugs, are associated with a 28 percent reduced risk of dementia compared to angiotensin-converting enzyme inhibitors (ACE inhibitors). This finding, published in the journal GeroScience on February 27, 2026, offers hope amid Australia's escalating dementia crisis, where an estimated 446,500 people are living with the condition as of 2026, a number projected to nearly double by 2054.

High blood pressure, or hypertension, affects approximately 34 percent of Australian adults—around 6.8 million people—and is a well-established modifiable risk factor for dementia. By examining real-world data from over 51,000 hypertensive patients aged 45 and older, the University of Tasmania team provides actionable insights into optimizing treatment choices for long-term brain health. This study not only underscores the value of university-led research in public health but also emphasizes the importance of personalized medicine in preventing cognitive decline.

The Hypertension-Dementia Connection in Australia

Hypertension silently damages blood vessels throughout the body, including those in the brain, leading to reduced cerebral blood flow, vascular damage, and increased amyloid plaque buildup—hallmarks of Alzheimer's disease and vascular dementia. In Australia, where dementia has recently overtaken heart disease as the leading cause of death, understanding these links is critical. The Australian Institute of Health and Welfare reports that uncontrolled high blood pressure contributes significantly to the nation's dementia burden, with prevalence rising sharply after age 65.

Both ARBs and ACE inhibitors lower blood pressure by targeting the renin-angiotensin system (RAS), a hormonal pathway that regulates vascular tone. ACE inhibitors block the conversion of angiotensin I to angiotensin II, while ARBs directly prevent angiotensin II from binding to its receptors. Despite similar efficacy in blood pressure control, emerging evidence suggests ARBs may offer superior neuroprotective effects, potentially due to better penetration of the blood-brain barrier and modulation of brain inflammation.

Unpacking the 45 and Up Study: Australia's Premier Ageing Cohort

The 45 and Up Study, managed by the Sax Institute, is a powerhouse of Australian health research, recruiting over 267,000 participants aged 45 and older from New South Wales between 2006 and 2009. Linked to administrative datasets like hospital records, Pharmaceutical Benefits Scheme (PBS) dispensing data, and death registries via the Secure E-Research platform, it enables robust, population-level analyses. University of Tasmania researchers leveraged this resource to track long-term outcomes, providing a gold standard for observational studies in higher education-driven public health investigations.

This cohort's strength lies in its representativeness and depth, capturing lifestyle factors such as diet quality (via the Australian Recommended Food Score) and physical activity levels, which were adjusted for in the analysis to isolate medication effects.

Study Design and Methodology: Rigorous and Innovative

The prospective cohort included patients initiating ARB or ACE inhibitor therapy from 2004 to mid-2022, with at least 80 percent adherence (proportion of days covered) to one class exclusively. After propensity score matching on 40 confounders—including age, sex, comorbidities like diabetes and atrial fibrillation, smoking, and baseline medications—the final sample comprised 51,574 individuals (mean age 66.3 years, 48 percent women), followed for a mean of 11.3 years.

Dementia was ascertained through hospital diagnoses (ICD-10 codes), emergency visits, anti-dementia prescriptions, and mortality data. Cox proportional hazards models estimated hazard ratios (HR), with sensitivity analyses confirming robustness against competing risks like death and alternative weighting methods.

• Matching Balance: Achieved excellent covariate balance (standardized mean difference <0.1).
• Adherence Threshold: ≥80 percent PDC ensured chronic exposure.
• Adjustments: Diet, exercise, NSAIDs, statins, and mental health conditions.

Key Findings: ARBs' Edge in Dementia Prevention

The headline result: ARB users faced a 28 percent lower dementia risk (HR 0.72, 95% CI 0.65-0.80, p<0.001) versus ACE inhibitor users. Incidence rates were 6.2 versus 8.7 per 1,000 person-years. Benefits held across sexes and persisted after lifestyle adjustments.

ARB use also correlated with lower all-cause mortality (HR 0.77, 95% CI 0.73-0.82) and dementia-attributable deaths (HR 0.81, 95% CI 0.74-0.89), suggesting multifaceted protective effects.

Agent-Specific Insights: Not All Drugs Are Equal

Exploratory analyses revealed variations: Compared to lisinopril (common ACEI), olmesartan (HR 0.32), candesartan (0.41), telmisartan (0.42), and irbesartan (0.45) showed strongest protection. Perindopril (ACEI) was better than lisinopril (HR 0.52), while captopril worsened risk (HR 4.9). These differences may stem from lipophilicity, PPAR-gamma agonism in select ARBs, or receptor affinities.

In Australia, PBS data indicates both classes are staples—perindopril leads ACEIs, with ARBs like candesartan rising—offering prescribers evidence to prioritize.

Biological Mechanisms: Why ARBs May Excel

ARBs' advantages likely transcend blood pressure reduction. Unlike ACEIs, many ARBs (e.g., telmisartan, olmesartan) cross the blood-brain barrier, activating protective AT2 and AT4 receptors while blocking harmful AT1 signaling. This curbs neuroinflammation, oxidative stress, amyloid-beta accumulation, and tau hyperphosphorylation—core dementia pathologies.

Preclinical studies show ARBs enhance cerebral perfusion, reduce microglial activation, and boost neurogenesis. Clinical meta-analyses corroborate lower dementia odds with ARBs. For more on mechanisms, see this Frontiers review.

Implications for Australian Healthcare and Policy

Australia's Pharmaceutical Benefits Scheme subsidizes both classes, but shifting toward ARBs could yield substantial savings—preventing dementia cases amid rising prevalence. With hypertension undertreated in one-third of cases, GPs might favor ARBs for at-risk patients, aligning with guidelines emphasizing RAS inhibitors.

University of Tasmania's work exemplifies how targeted pharmacoepidemiology drives evidence-based practice. Policymakers could incentivize ARB use via PBS, while public campaigns promote hypertension screening. See Dementia Australia's prevalence estimates for LGA-level insights.

Expert Perspectives and Broader Evidence

Lead author Eyayaw Ashete Belachew noted: “Our findings suggest that not all blood pressure medications have the same impact on long-term brain health... ARBs may offer additional benefits.” This aligns with global studies, like a 2025 multi-country analysis (HR 0.87 for ARBs) and U.S. data favoring BBB-penetrating ARBs.

In Australia, similar trends emerge from ASPREE and other cohorts. For full study details, access the GeroScience publication or Sax Institute summary here.

Limitations, Future Directions, and University Contributions

Observational design limits causality; residual confounding possible despite matching. Agent analyses exploratory due to smaller samples. RCTs like planned ARB trials are needed. UTAS's Menzies Institute continues RAS-dementia research, fostering PhD opportunities and collaborations.

Photo by KOMMERS on Unsplash

• Future: Head-to-head RCTs, genetic subgroups, combination therapies.
• Actionable: Discuss ARBs with GPs if hypertensive; monitor adherence.

Pathways Forward: Research Careers in Australian Academia

This UTAS-led breakthrough spotlights pharmacoepidemiology's impact, attracting talent to Australian universities. With dementia's economic toll exceeding $15 billion annually, investing in higher education research yields dividends. Aspiring researchers can explore roles at UTAS or via national networks like the Sax Institute.